PLx Pharma Inc (PLXP) Actualités

Form 15-12G - Securities registration termination [Section 12(g)]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Current Report Filing (8-k)

0001497504 false --12-31 0001497504 2023-05-26 2023-05-26 iso4217:USD...

PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is...

PLx Pharma Inc. Receives Nasdaq Delisting Notice

SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is...

Current Report Filing (8-k)

0001497504 false 0001497504 2023-04-04 2023-04-04 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001497504 false 0001497504 2023-03-07 2023-03-07 iso4217:USD xbrli:shares...

Amended Statement of Ownership (sc 13g/a)

CUSIP No. 72942A107       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

0001497504 false 0001497504 2023-01-14 2023-01-14 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001497504 false 0001497504 2022-11-08 2022-11-08 iso4217:USD xbrli:shares...

Quarterly Report (10-q)

0001497504 PLx Pharma Inc. false --12-31 Q3 2022 0.001 0.001 12,642,000 12,642,000 45,000 45,000 12,642 12,642 12,642 12,642 0.00...